Status:
COMPLETED
Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Chronic Heart Failure
Eligibility:
All Genders
Brief Summary
Secondary Data Collection Study; Safety And Effectiveness Of Selara Under Japanese Medical Practice
Detailed Description
This study will be conducted under the central registration system until the number of subjects who meet the conditions for registration reaches the target number of subjects. The patients will be obs...
Eligibility Criteria
Inclusion
- Patients in whom treatment with this drug is for CHF. The indications at approval for this drug are as follows. When using this drug, refer to the latest package insert of this drug.
Exclusion
- Patients who were previously registered for this study. Patients who received eplerenone within the past three months regardless of the reason for use.
Key Trial Info
Start Date :
July 5 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 15 2020
Estimated Enrollment :
1165 Patients enrolled
Trial Details
Trial ID
NCT03342690
Start Date
July 5 2017
End Date
July 15 2020
Last Update
July 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Local Country Office
Tokyo, Japan